Previous 10 | Next 10 |
NASDAQ, TSX: NVCN VANCOUVER , Sept. 4, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices fo...
The European Society of Cardiology Includes Neovasc Reducer™ for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes Canada NewsWire VANCOUVER, Sept. 3, 2019 Announcement Made at Europ...
Announcement Made at European Society of Cardiology Congress 2019 in Paris, France NASDAQ, TSX: NVCN VANCOUVER , Sept. 3, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral ...
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency Canada NewsWire VANCOUVER, Aug. 22, 2019 NASDAQ, TSX: NVCN VANCOUVER , Aug. 22, 2019 /CNW/ - ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), announced today that it has received ...
Neovasc Inc. (NVCN) Q2 2019 Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Fred Colen – President and Chief Executive Officer Chris Clark – Chief Financial Officer Conference Call Participants ...
Neovasc (NASDAQ: NVCN ): Q2 GAAP EPS of -$1.17 beats by $0.18 . Revenue of $0.44M (+7.3% Y/Y) misses by $0.23M . Shares -1.6% . Press Release More news on: Neovasc Inc., Earnings news and commentary, Healthcare stocks news, ,
NASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the "Reducer") for CCS class IV patients and to meet for another Sprint discussion Closed Private Placement of Convertible De...
Presentation Scheduled for 11:30 am Eastern Time on August 8 th NASDAQ, TSX: NVCN VANCOUVER , Aug. 5, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replace...
Conference Call Scheduled for 4:30 pm Eastern Time on August 7 th NASDAQ, TSX: NVCN VANCOUVER , Aug. 2, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve repla...
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency Canada NewsWire VANCOUVER, July 17, 2019 NASDAQ, TSX: NVCN VANCOUVER , July 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) ...
News, Short Squeeze, Breakout and More Instantly...
Neovasc Inc. (NASDAQ: NVCN) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.48% on the day to $29.23. Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. It...
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Hi...
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as d...